LEADER 01310nam  2200373Ia 450 
001 9910696977703321
005 20230902161909.0
035   $a(CKB)5470000002383112
035   $a(OCoLC)535506920
035   $a(EXLCZ)995470000002383112
100   $a20100302d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $egenotoxic and carcinogenic impurities in drug substances and products, recommended approaches
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2008]
215   $a1 online resource (13 pages) $cchart
300   $a"Draft guidance."
300   $a"Pharmacology and toxicology."
300   $a"December 2008."
517   $aGuidance for industry 
606   $aGenetic toxicology$zUnited States
606   $aDrugs$xCarcinogenicity$zUnited States
615  0$aGenetic toxicology
615  0$aDrugs$xCarcinogenicity
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910696977703321
996   $aGuidance for industry$93434577
997   $aUNINA